ESMO肺癌集锦的学习课件.pptxVIP

ESMO肺癌集锦的学习课件第1页/共31页 GOOD SIENCEBETTER MEDICINE BEST PRACTICEESMO Highlights Part A第2页/共31页 ESMO Highlights 2010 Lung Cancer第3页/共31页 A randomized phase III study comparing gefitinib with carboplatin/ paclitaxel for the first-line treatment of non-small cell lung cancer with sensitive EGFR mutations: NEJ002 studyAkira Inoue et alOn behalf of the North-East Japan Study Group, Tohoku University Hospital, Sendai, JapanInoue et al. ECCO-ESMO 2009; Abstract 9LBA第4页/共31页 Study designPrimary endpoint: Progression-free survival (PFS)Secondary endpoints: Overall survival, overall response rate, t